<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">35163674</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>03</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Gene Transfer of Skeletal Muscle-Type Myosin Light Chain Kinase via Adeno-Associated Virus 6 Improves Muscle Functions in an Amyotrophic Lateral Sclerosis Mouse Model.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1747</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms23031747</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that shows progressive muscle weakness. A few treatments exist including symptomatic therapies, which can prolong survival or reduce a symptom; however, no fundamental therapies have been found. As a therapeutic strategy, enhancing muscle force is important for patients' quality of life. In this study, we focused on skeletal muscle-specific myosin regulatory light chain kinase (skMLCK), which potentially enhances muscle contraction, as overexpression of skMLCK was thought to improve muscle function. The adeno-associated virus serotype 6 encoding skMLCK (AAV6/skMLCK) and eGFP (control) was produced and injected intramuscularly into the lower limbs of SOD1<sup>G37R</sup> mice, which are a familial ALS model. AAV6/skMLCK showed the successful expression of skMLCK in the muscle tissues. Although the control did not affect the muscle force in both of the WT and SOD1<sup>G37R</sup> mice, AAV6/skMLCK enhanced the twitch force of SOD1<sup>G37R</sup> mice and the tetanic force of WT and SOD1<sup>G37R</sup> mice. These results indicate that overexpression of skMLCK can enhance the tetanic force of healthy muscle as well as rescue weakened muscle function. In conclusion, the gene transfer of skMLCK has the potential to be a new therapy for ALS as well as for other neuromuscular diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oya</LastName><ForeName>Ryohei</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-8991-0315</Identifier><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Osaka University Graduate School of Medicine/Frontier Biosciences, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsukamoto</LastName><ForeName>Osamu</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Osaka University Graduate School of Medicine/Frontier Biosciences, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hitsumoto</LastName><ForeName>Tatsuro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Osaka University Graduate School of Medicine/Frontier Biosciences, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakahara</LastName><ForeName>Naoya</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Molecular Physiology, The Jikei University School of Medicine, Tokyo 105-8461, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okamoto</LastName><ForeName>Chisato</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0671-793X</Identifier><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Osaka University Graduate School of Medicine/Frontier Biosciences, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuoka</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Osaka University Graduate School of Medicine/Frontier Biosciences, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Hisakazu</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-4619-3680</Identifier><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Osaka University Graduate School of Medicine/Frontier Biosciences, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inohara</LastName><ForeName>Hidenori</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takashima</LastName><ForeName>Seiji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Osaka University Graduate School of Medicine/Frontier Biosciences, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>17K09578, 18K15366</GrantID><Agency>Japan Society for the Promotion of Science</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.11.18</RegistryNumber><NameOfSubstance UI="D009219">Myosin-Light-Chain Kinase</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000623765">Adeno-associated virus-1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001696" MajorTopicYN="N">Biomechanical Phenomena</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000229" MajorTopicYN="N">Dependovirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018014" MajorTopicYN="Y">Gene Transfer Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007273" MajorTopicYN="N">Injections, Intramuscular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009219" MajorTopicYN="N">Myosin-Light-Chain Kinase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013746" MajorTopicYN="N">Tetany</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adeno-associated virus 6</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">gene therapy</Keyword><Keyword MajorTopicYN="N">muscle function</Keyword><Keyword MajorTopicYN="N">myosin light chain kinase</Keyword></KeywordList><CoiStatement>The authors have no conflict of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>15</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35163674</ArticleId><ArticleId IdType="pmc">PMC8836241</ArticleId><ArticleId IdType="doi">10.3390/ijms23031747</ArticleId><ArticleId IdType="pii">ijms23031747</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Van Es M.A., Hardiman O., Chio A., Al-Chalabi A., Pasterkamp R.J., Veldink J.H., van den Berg L.H. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Robberecht W., Philips T. The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 2013;14:248&#x2013;264. doi: 10.1038/nrn3430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3430</ArticleId><ArticleId IdType="pubmed">23463272</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O., Al-Chalabi A., Chio A., Corr E.M., Logroscino G., Robberecht W., Shaw P.J., Simmons Z., van den Berg L.H. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Julien J.P., Kriz J. Transgenic mouse models of amyotrophic lateral sclerosis. Biochim. Biophys. Acta. 2006;1762:1013&#x2013;1024. doi: 10.1016/j.bbadis.2006.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2006.03.006</ArticleId><ArticleId IdType="pubmed">16675207</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A., Hardiman O. The epidemiology of ALS: A conspiracy of genes, environment and time. Nat. Rev. Neurol. 2013;9:617&#x2013;628. doi: 10.1038/nrneurol.2013.203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur S.J., McKeown S.R., Rashid S. Mutant SOD1 mediated pathogenesis of Amyotrophic Lateral Sclerosis. Gene. 2016;577:109&#x2013;118. doi: 10.1016/j.gene.2015.11.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2015.11.049</ArticleId><ArticleId IdType="pubmed">26657039</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M., Hart P.J., Borchelt D.R., Andersen P.M. Variation in aggregation propensities among ALS-associated variants of SOD1: Correlation to human disease. Hum. Mol. Genet. 2009;18:3217&#x2013;3226. doi: 10.1093/hmg/ddp260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp260</ArticleId><ArticleId IdType="pmc">PMC2722984</ArticleId><ArticleId IdType="pubmed">19483195</ArticleId></ArticleIdList></Reference><Reference><Citation>Mead R.J., Bennett E.J., Kennerley A.J., Sharp P., Sunyach C., Kasher P., Berwick J., Pettmann B., Battaglia G., Azzouz M., et al. Optimised and Rapid Pre-clinical Screening in the SOD1G93A Transgenic Mouse Model of Amyotrophic Lateral Sclerosis (ALS) PLoS ONE. 2011;6:e23244. doi: 10.1371/journal.pone.0023244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0023244</ArticleId><ArticleId IdType="pmc">PMC3158065</ArticleId><ArticleId IdType="pubmed">21876739</ArticleId></ArticleIdList></Reference><Reference><Citation>Reaume A.G., Elliott J.L., Hoffman E.K., Kowall N.W., Ferrante R.J., Siwek D.F., Wilcox H.M., Flood D.G., Beal M.F., Brown R.H., Jr., et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat. Genet. 1996;13:43&#x2013;47. doi: 10.1038/ng0596-43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0596-43</ArticleId><ArticleId IdType="pubmed">8673102</ArticleId></ArticleIdList></Reference><Reference><Citation>Valentine J.S., Doucette P.A., Zittin Potter S. Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis. Annu. Rev. Biochem. 2005;74:563&#x2013;593. doi: 10.1146/annurev.biochem.72.121801.161647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biochem.72.121801.161647</ArticleId><ArticleId IdType="pubmed">15952898</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn L.I., Houseweart M.K., Kato S., Anderson K.L., Anderson S.D., Ohama E., Reaume A.G., Scott R.W., Cleveland D.W. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science. 1998;281:1851&#x2013;1854. doi: 10.1126/science.281.5384.1851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.281.5384.1851</ArticleId><ArticleId IdType="pubmed">9743498</ArticleId></ArticleIdList></Reference><Reference><Citation>Ezzi S.A., Urushitani M., Julien J.P. Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J. Neurochem. 2007;102:170&#x2013;178. doi: 10.1111/j.1471-4159.2007.04531.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04531.x</ArticleId><ArticleId IdType="pubmed">17394546</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco D.A., Morfini G., Karabacak N.M., Song Y., Gros-Louis F., Pasinelli P., Goolsby H., Fontaine B.A., Lemay N., McKenna-Yasek D., et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat. Neurosci. 2010;13:1396&#x2013;1403. doi: 10.1038/nn.2660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2660</ArticleId><ArticleId IdType="pmc">PMC2967729</ArticleId><ArticleId IdType="pubmed">20953194</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel P., Kriz J., Gravel M., Soucy G., Bareil C., Gravel C., Julien J.P. Adeno-associated Virus-Mediated Delivery of a Recombinant Single-Chain Antibody Against Misfolded Superoxide Dismutase for Treatment of Amyotrophic Lateral Sclerosis. Mol. Ther. 2014;22:498&#x2013;510. doi: 10.1038/mt.2013.239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2013.239</ArticleId><ArticleId IdType="pmc">PMC3944333</ArticleId><ArticleId IdType="pubmed">24394188</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris S.P., Likanje M.N., Andrews J.A. Amyotrophic lateral sclerosis: Update on clinical management. Curr. Opin. Neurol. 2020;33:641&#x2013;648. doi: 10.1097/WCO.0000000000000864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000864</ArticleId><ArticleId IdType="pubmed">32868602</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T., Cudkowicz M., Shaw P.J., Andersen P.M., Atassi N., Bucelli R.C., Genge A., Glass J., Ladha S., Ludolph A.L., et al. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 2020;383:109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukamoto O., Kitakaze M. Biochemical and physiological regulation of cardiac myocyte contraction by cardiac-specific myosin light chain kinase. Circ. J. 2013;77:2218&#x2013;2225. doi: 10.1253/circj.CJ-13-0627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.CJ-13-0627</ArticleId><ArticleId IdType="pubmed">23863751</ArticleId></ArticleIdList></Reference><Reference><Citation>Stull J.T., Kamm K.E., Vandenboom R. Myosin Light Chain Kinase and the Role of Myosin Light Chain Phosphorylation in Skeletal Muscle. Arch. Biochem. Biophys. 2011;510:120&#x2013;128. doi: 10.1016/j.abb.2011.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abb.2011.01.017</ArticleId><ArticleId IdType="pmc">PMC3101293</ArticleId><ArticleId IdType="pubmed">21284933</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore R.L., Houston M.E., Iwamoto G.A., Stull J.T. Phosphorylation of rabbit skeletal muscle myosin in situ. J. Cell Physiol. 1985;125:301&#x2013;305. doi: 10.1002/jcp.1041250219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.1041250219</ArticleId><ArticleId IdType="pubmed">4055914</ArticleId></ArticleIdList></Reference><Reference><Citation>Seguchi O., Takashima S., Yamazaki S., Asakura M., Asano Y., Shintani Y., Wakeno M., Minamino T., Kondo H., Furukawa H., et al. A cardiac myosin light chain kinase regulates sarcomere assembly in the vertebrate heart. J. Clin. Investig. 2007;117:2812&#x2013;2824. doi: 10.1172/JCI30804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI30804</ArticleId><ArticleId IdType="pmc">PMC1978424</ArticleId><ArticleId IdType="pubmed">17885681</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhi G., Ryder J.W., Huang J., Ding P., Chen Y., Zhao Y., Kamm K.E., Stull J.T. Myosin light chain kinase and myosin phosphorylation effect frequency-dependent potentiation of skeletal muscle contraction. Proc. Natl. Acad. Sci. USA. 2005;102:17519&#x2013;17524. doi: 10.1073/pnas.0506846102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506846102</ArticleId><ArticleId IdType="pmc">PMC1297671</ArticleId><ArticleId IdType="pubmed">16299103</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryder J.W., Lau K.S., Kamm K.E., Stull J.T. Enhanced skeletal muscle contraction with myosin light chain phosphorylation by a calmodulin-sensing kinase. J. Biol. Chem. 2007;282:20447&#x2013;20454. doi: 10.1074/jbc.M702927200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M702927200</ArticleId><ArticleId IdType="pubmed">17504755</ArticleId></ArticleIdList></Reference><Reference><Citation>Pichavant C., Aartsma-Rus A., Clemens P.R., Davies K.E., Dickson G., Takeda S., Wilton S.D., Wolff J.A., Wooddell C.I., Xiao X., et al. Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol. Ther. 2011;19:830&#x2013;840. doi: 10.1038/mt.2011.59.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2011.59</ArticleId><ArticleId IdType="pmc">PMC3098643</ArticleId><ArticleId IdType="pubmed">21468001</ArticleId></ArticleIdList></Reference><Reference><Citation>Chamberlain J.R., Chamberlain J.S. Progress toward Gene Therapy for Duchenne Muscular Dystrophy. Mol. Ther. 2017;25:1125&#x2013;1131. doi: 10.1016/j.ymthe.2017.02.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2017.02.019</ArticleId><ArticleId IdType="pmc">PMC5417844</ArticleId><ArticleId IdType="pubmed">28416280</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Zaidy S.A., Mendell J.R. From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1. Pediatr. Neurol. 2019;100:3&#x2013;11. doi: 10.1016/j.pediatrneurol.2019.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pediatrneurol.2019.06.007</ArticleId><ArticleId IdType="pubmed">31371124</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemaladewi D.U., Bassi P.S., Erwood S., Al-Basha D., Gawlik K.I., Lindsay K., Hyatt E., Kember R., Place K.M., Marks R.M., et al. A mutation-independent approach for muscular dystrophy via upregulation of a modifier gene. Nature. 2019;572:125&#x2013;130. doi: 10.1038/s41586-019-1430-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1430-x</ArticleId><ArticleId IdType="pubmed">31341277</ArticleId></ArticleIdList></Reference><Reference><Citation>Bravo-Hernandez M., Tadokoro T., Navarro M.R., Platoshyn O., Kobayashi Y., Marsala S., Miyanohara A., Juhas S., Juhasova J., Skalnikova H., et al. Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS. Nat. Med. 2020;26:118&#x2013;130. doi: 10.1038/s41591-019-0674-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0674-1</ArticleId><ArticleId IdType="pmc">PMC8171115</ArticleId><ArticleId IdType="pubmed">31873312</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J.M., Andrews J.A., Genge A., Jackson C., Lechtzin N., Miller T.M., Cockroft B.M., Meng L., Wei J., Wolff A.A., et al. A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial of Reldesemtiv in Patients with ALS. Amyotroph. Lateral Scler. Front. Degener. 2021;22:287&#x2013;299. doi: 10.1080/21678421.2020.1822410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1822410</ArticleId><ArticleId IdType="pmc">PMC8117790</ArticleId><ArticleId IdType="pubmed">32969758</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi M., Kimura M., Li Z.B., Ohno T., Takemori S., Hoh J.F., Yagi N. X-ray diffraction analysis of the effects of myosin regulatory light chain phosphorylation and butanedione monoxime on skinned skeletal muscle fibers. Am. J. Physiol. Cell Physiol. 2016;310:C692&#x2013;C700. doi: 10.1152/ajpcell.00318.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00318.2015</ArticleId><ArticleId IdType="pmc">PMC4835919</ArticleId><ArticleId IdType="pubmed">26911280</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Zhong L., Nahid M.A., Gao G. The potential of adeno-associated viral vectors for gene delivery to muscle tissue. Expert Opin. Drug Deliv. 2014;11:345&#x2013;364. doi: 10.1517/17425247.2014.871258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17425247.2014.871258</ArticleId><ArticleId IdType="pmc">PMC4098646</ArticleId><ArticleId IdType="pubmed">24386892</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell J.R., Campbell K., Rodino-Klapac L., Sahenk Z., Shilling C., Lewis S., Bowles D., Gray S., Li C., Galloway G., et al. Dystrophin immunity in Duchenne&#x2019;s muscular dystrophy. N. Engl. J. Med. 2010;363:1429&#x2013;1437. doi: 10.1056/NEJMoa1000228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1000228</ArticleId><ArticleId IdType="pmc">PMC3014106</ArticleId><ArticleId IdType="pubmed">20925545</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodatsu A., Fujino N., Uyama Y., Tsukamoto O., Imai-Okazaki A., Yamazaki S., Seguchi O., Konno T., Hayashi K., Kawashiri M.A., et al. Impact of cardiac myosin light chain kinase gene mutation on development of dilated cardiomyopathy. ESC Heart Fail. 2019;6:406&#x2013;415. doi: 10.1002/ehf2.12410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.12410</ArticleId><ArticleId IdType="pmc">PMC6437445</ArticleId><ArticleId IdType="pubmed">30690923</ArticleId></ArticleIdList></Reference><Reference><Citation>Barton E.R. Viral Expression of Insulin-Like Growth factor-I Isoforms Promotes Different Responses in Skeletal Muscle. J. Appl. Physiol. 2006;100:1778&#x2013;1784. doi: 10.1152/japplphysiol.01405.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/japplphysiol.01405.2005</ArticleId><ArticleId IdType="pubmed">16439513</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimura M., Sakamoto M., Ikemoto M., Mochizuki Y., Yuasa K., Miyagoe-Suzuki Y., Takeda S. AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype. Mol. Ther. 2004;10:821&#x2013;828. doi: 10.1016/j.ymthe.2004.07.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2004.07.025</ArticleId><ArticleId IdType="pubmed">15509500</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita E., Kinoshita-Kikuta E., Koike T. History of Phos-tag technology for phosphoproteomics. J. Proteom. 2022;252:104432. doi: 10.1016/j.jprot.2021.104432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jprot.2021.104432</ArticleId><ArticleId IdType="pubmed">34818585</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy R.R., Meadows I.D., Baldwin K.M., Edgerton V.R. Functional significance of compensatory overloaded rat fast muscle. J. Appl. Physiol. Respir. Environ. Exerc. Physiol. 1982;52:473&#x2013;478. doi: 10.1152/jappl.1982.52.2.473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jappl.1982.52.2.473</ArticleId><ArticleId IdType="pubmed">7061301</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>